Three randomised controlled trials (RCTs)—Hendershot et al. (2025) [14], Klausen et al. (2022) [15], and Probst et al. (2023) [16]—involving 430 participants diagnosed with alcohol use disorder (AUD) were analysed to assess the effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes. The gene discussed is GLP1R; the disease is alcohol abuse.